DesRosier Thomas 4
4 · Seres Therapeutics, Inc. · Filed May 19, 2025
Insider Transaction Report
Form 4
DesRosier Thomas
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-05-15+111→ 7,366 total - Exercise/Conversion
Restricted Stock Units
2025-05-15−133→ 929 total→ Common Stock (133 underlying) - Exercise/Conversion
Restricted Stock Units
2025-05-15−111→ 1,224 total→ Common Stock (111 underlying) - Exercise/Conversion
Common Stock
2025-05-15+133→ 7,255 total - Sale
Common Stock
2025-05-15$7.28/sh−79$575→ 7,287 total
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]Reflects a 1-for-20 reverse stock split effected on April 21, 2025.
- [F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F4]The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F5]The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.